Sugi Predict

Sugi Predict / Compounds / SCHEMBL1630163

SCHEMBL1630163

SCHEMBL1630163

N#Cc1ccccc1-c1ccc(C(=O)NCCNC(=O)CCN)c(NCCc2cccc(F)c2)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ KISS1R Q969F8 6/20 0.38
▸ HIF1A Q16665 1/20 0.38
▸ TP53 P04637 1/20 0.38
▸ TAAR1 Q96RJ0 1/20 0.38
▸ RPS6KB1 P23443 1/20 0.37
▸ AKT1 P31749 1/20 0.37
▸ TSHR P16473 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ THRB P10828 1/20 0.36
▸ CCNT1 O60563 1/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ LTA4H P09960 1/20 0.35
▸ EPHX2 P34913 1/20 0.35
▸ TBK1 Q9UHD2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1632642 0.96 KDM4E (0.37) KDM4EMEN1MAPTKMT2AL3MBTL1
SCHEMBL1631134 0.94 KDM4E (0.39) KDM4EMEN1MAPTKMT2AL3MBTL1
SCHEMBL1630874 0.93 KISS1R (0.41) KDM4EMEN1MAPTKMT2AL3MBTL1
SCHEMBL1632321 0.92 KDM4E (0.39) KDM4EMEN1MAPTKMT2AL3MBTL1
SCHEMBL1631991 0.92 KDM4E (0.40) KDM4EMEN1MAPTKMT2AL3MBTL1
SCHEMBL1631990 0.91 KDM4E (0.39) KDM4EMEN1MAPTKMT2AL3MBTL1
SCHEMBL1631543 0.90 KDM4E (0.39) KDM4EMEN1MAPTKMT2AL3MBTL1
SCHEMBL1630893 0.90 KDM4E (0.39) KDM4EMEN1MAPTKMT2AL3MBTL1
SCHEMBL1632756 0.90 RPS6KB1 (0.40) KDM4EMEN1MAPTKMT2AL3MBTL1
SCHEMBL1631377 0.89 RPS6KB1 (0.39) KDM4EMEN1MAPTKMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090012126-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2009-01-08 — — US claimed
US-7932270-B2 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. (US) 2011-04-26 — — US disclosed
US-7932270-B2 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. (US) 2011-04-26 — — US disclosed
US-7932270-B2 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. (US) 2011-04-26 — — US disclosed
US-20090012126-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2009-01-08 — — US disclosed
US-20090012126-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2009-01-08 — — US disclosed
US-20090012126-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2009-01-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012126-A1 Certain chemical entities, compositions, and methods MYLK, MYH2, MYH10 KDM4E 3309/4885MEN1 510/4885MAPT 540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.